[ET Net News Agency, 4 October 2021] Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
(02196) said the company, Asia Energy Investment, Qianhai Zhitou, the purchaser and Yaneng
Biotech, a subsidiary of the company, have entered into the equity transfer and capital
increase agreement in relation to, among others, (1) each of the vendors agrees to
transfer their respective sale interest to the purchaser for an aggregate consideration of
RMB2,203.9875 million, of which the company agrees to transfer the Fosun Pharma Sale
Interest to the purchaser for the consideration in the amount of RMB1,596.1 million; and
(2) the purchaser agrees to make a capital contribution in the amount of RMB300 million to
subscribe for an additional registered capital of HK$634,624 of Yaneng Biotech.
The Fosun Pharma Sale Interest is (1) 29.0200% of the registered capital of Yaneng
Biotech; and (2) 100% equity interest in Jinshi Laboratory held by Fosun Diagnostics. (RC)